Erythromycin
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Erythromycin: Punctate epithelial keratoconjunctivitis
One-Sentence Summary
Erythromycin is a macrolide antibiotic that blocks bacterial protein synthesis and also has anti-inflammatory activity. The TxGNN model predicts it may be useful for punctate epithelial keratoconjunctivitis, but so far there are no registered clinical trials and only 1 publication (a pediatric review), so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Erythromycin is a macrolide. It binds the bacterial 50S ribosomal subunit and stops protein synthesis, and it also has anti-inflammatory effects. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the general pharmacology of the macrolide class.
Punctate epithelial keratoconjunctivitis and related chronic blepharokeratoconjunctivitis involve ocular surface inflammation, often linked to meibomian gland dysfunction and bacterial overgrowth. In that setting, a drug with both antibacterial and anti-inflammatory activity could plausibly help. Topical and systemic macrolides are used in related eyelid and ocular surface conditions.
This link is plausible but indirect. The only retrieved paper is a general review of the diagnosis and management of chronic blepharokeratoconjunctivitis in children. It is not a study of erythromycin in punctate epithelial keratoconjunctivitis itself. Because no cited study directly examines this disease, the evidence level is L5 (model prediction only).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11495307 | 2001 | Review | Journal of Pediatric Ophthalmology and Strabismus | Describes history, symptoms, signs and treatment of chronic blepharokeratoconjunctivitis in children; does not test erythromycin directly for the predicted disease |
India Market Information
At least 20 licences are recorded, all valid, and the list may be partial. Five main licences:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 78989 | Erythrocin Granules (Pfizer Ltd) | Granules, sachet of 30 ml | Not stated in licence record |
| 80278 | Erythrox 250mg Tablet (Medicraft Group) | Tablet, strip of 10 | Not stated in licence record |
| 79299 | Eromed 125mg Suspension (Comed Chemicals Ltd) | Suspension, bottle of 60 ml | Not stated in licence record |
| 5250 | Acnebenz Gel (A. Menarini India Pvt Ltd) | Topical gel, tube of 60 g | Not stated in licence record |
| 79419 | Erylent Gel (Talent Healthcare) | Topical gel, tube of 20 g | Not stated in licence record |
Available forms include oral tablets, granules and suspensions, and topical gels. No ophthalmic form appears among the recorded licences.
Safety Considerations
- Contraindications / cautions in related conditions: Erythromycin is linked to caution in long QT syndrome, torsades de pointes, porphyria, kidney disease, liver disease, haematologic disease, myasthenia gravis and other neuromuscular junction disease, hearing disorders, Clostridium difficile colitis, and exfoliative dermatitis or dermatitis. This list is not drawn from label text.
- Drug Interactions: 755 interactions were recorded. Major-level ones include clarithromycin and loperamide. Moderate-level ones include corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), famotidine, cimetidine, pioglitazone, aprepitant and alosetron. QT-prolonging and CYP3A4-interacting combinations deserve particular attention.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high (0.9989), and the mechanism is plausible given erythromycin’s antibacterial and anti-inflammatory activity. However, there are no clinical trials and no study directly examining this disease, so the evidence rests on the model prediction alone.
To proceed, the following is needed:
- Studies or case series of erythromycin, preferably topical ophthalmic, in punctate epithelial keratoconjunctivitis
- Confirmed mechanism-of-action data
- Package insert warnings and contraindications, which are currently missing
- Assessment of whether an ophthalmic formulation is available, since no ophthalmic form is among the recorded licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.